DUBLIN--(BUSINESS WIRE)--The "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's offering.
The report "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" details the key points (etiology, epidemiology, current treatment, products currently marketed and in pipeline, market drivers and barriers) driving the Colorectal Cancer (CRC) market in the five Asia-Pacific (APAC) markets: India, China, Australia, South Korea and Japan.
Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 50 and over, a high-risk age range for Colorectal Cancer (CRC). Over half of the incident cases of Colorectal Cancer (CRC) are diagnosed in patients over the age of 50. Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally, accounting for 0.77 million deaths in 2015.
The five-year prevalence population for Colorectal Cancer (CRC) in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles. However, growing awareness of the disease and associated risk factors together with the availability of free testing services for Colorectal Cancer (CRC) patients will increase early diagnosis and the treatment-receiving population, including targeted treatment, driving demand and contributing to market growth. Increasing affordability and healthcare access in India and China are also likely to contribute to the growth of the treatment-receiving pool significantly.
On the other hand, the poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The Colorectal Cancer (CRC) market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.
Market Dynamics
Drivers
- Increasing Elderly Population and Incidence of CRC
- Increasing Screening Programs and Approval of New Screening Tests for CRC to Drive Early Diagnosis Rate
- Increase in Mutation Testing to Drive Market Growth
- Availability of Novel First-, Second- and Third-Line Therapy Options in Pipeline
- Diversified Healthcare Reform to Boost Market Growth
- Diversified Health Insurance System to Help Nurture Growth
Barriers
- Patent Expiration of Branded Therapies to Affect CRC Market Growth
- High Prices of Therapeutics to Slow Down Market Growth
- Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm
- Lack of Development of Neoadjuvant and Adjuvant Pipeline Products
- Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India
- Drug Pricing Reforms
Key Topics Covered:
1 Table of Contents
2 Introduction
3 Marketed Products
4 Pipeline Analysis
5 Clinical Trial Analysis
6 Multi-scenario Forecast
7 Drivers and Barriers
8 Deals and Strategic Consolidations
9 Appendix
Companies Mentioned
- Taiho Pharma
- Merck KGaA
- Amgen
- Takeda
- Roche
- Eli Lilly
- Sanofi
- Regeneron
- Bayer
- Onyx
- Bristol-Myers Squib
- Sumitomo Dainippon Pharma
- Array BioPharma
- Hutchison MediPharma
- Jiangsu Hengrui Medicine
- Jiangsu Chia-Tai Tianqing
- Suzhou Zelgen Biopharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/p36ntd/asiapacific?w=4
